SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-23-024544
Filing Date
2023-05-26
Accepted
2023-05-26 16:47:06
Documents
16
Period of Report
2023-05-26
Items
Item 1.02: Termination of a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K sndx-20230526.htm   iXBRL 8-K 72508
2 EX-1.1 sndx-ex1_1.htm EX-1.1 440285
3 EX-5.1 sndx-ex5_1.htm EX-5.1 21762
4 GRAPHIC img160177385_0.jpg GRAPHIC 2124
5 GRAPHIC img160177385_1.jpg GRAPHIC 2124
  Complete submission text file 0000950170-23-024544.txt   723331

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT sndx-20230526_pre.xml EX-101.PRE 10229
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT sndx-20230526_lab.xml EX-101.LAB 13916
8 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT sndx-20230526.xsd EX-101.SCH 2463
10 EXTRACTED XBRL INSTANCE DOCUMENT sndx-20230526_htm.xml XML 4869
Mailing Address 35 GATEHOUSE DRIVE BUILDING D, FLOOR 3 WALTHAM MA 02451
Business Address 35 GATEHOUSE DRIVE BUILDING D, FLOOR 3 WALTHAM MA 02451 781-419-1400
Syndax Pharmaceuticals Inc (Filer) CIK: 0001395937 (see all company filings)

IRS No.: 320162505 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37708 | Film No.: 23969841
SIC: 2834 Pharmaceutical Preparations